Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;30(8):589-596.
doi: 10.2174/0113816128291248240131102709.

Relationship between Compound α-Ketoacid and Microinflammation in Patients with Chronic Kidney Disease

Zaobin Chen  1 , Yongda Lin  1 , Jiali Wang  1 , Kaijin Yao  1 , Yina Xie  1 , Xiutian Chen  1 , Tianbiao Zhou  1
Affiliations
Review

Relationship between Compound α-Ketoacid and Microinflammation in Patients with Chronic Kidney Disease

Zaobin Chen et al. Curr Pharm Des. 2024.

Abstract

Chronic kidney disease (CKD) refers to the presence of structural or functional abnormalities in the kidneys that affect health, lasting for more than 3 months. CKD is not only the direct cause of global incidence rate and mortality, but also an important risk factor for cardiovascular disease. Persistent microinflammatory state has been recognized as an important component of CKD, which can lead to renal fibrosis and loss of renal function, and plays a crucial role in the pathophysiology and progression of the disease. Simultaneously, compound α-Ketoacid can bind nitrogen-containing metabolites in the blood and accelerate their excretion from the body, thereby reducing the level of metabolic waste, alleviating gastrointestinal reactions in patients, and reducing the inflammatory response and oxidative stress state of the body. Compound α-Ketoacid contains amino acids required by CKD patients. In this review, we explore the relationship between compound α-Ketoacid and microinflammation in patients with CKD. The review indicated that compound α-Ketoacid can improve the microinflammatory state in CKD patients by improving the nutritional status of CKD patients, improving patient's acid-base balance disorder, regulating oxidative stress, improving gut microbiota, and regulating abnormal lipid metabolism.

Keywords: Compound α-Ketoacid; abnormal lipid metabolism.; chronic kidney disease; gut microbiota; micro inflammatory; nitrogen-containing metabolites; oxidative stress.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Rovin B.H.; Adler S.G.; Barratt J.; Bridoux F.; Burdge K.A.; Chan T.M.; Cook H.T.; Fervenza F.C.; Gibson K.L.; Glassock R.J.; Jayne D.R.W.; Jha V.; Liew A.; Liu Z-H.; Mejía-Vilet J.M.; Nester C.M.; Radhakrishnan J.; Rave E.M.; Reich H.N.; Ronco P.; Sanders J-S.F.; Sethi S.; Suzuki Y.; Tang S.C.W.; Tesar V.; Vivarelli M.; Wetzels J.F.M.; Floege J.; KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021,100(4),S1-S276 - DOI - PubMed
    1. Chen T.K.; Knicely D.H.; Grams M.E.; Chronic kidney disease diagnosis and management. JAMA 2019,322(13),1294-1304 - DOI - PubMed
    1. Bikbov B.; Purcell C.A.; Levey A.S.; Smith M.; Abdoli A.; Abebe M.; Adebayo O.M.; Afarideh M.; Agarwal S.K.; Agudelo-Botero M.; Ahmadian E.; Al-Aly Z.; Alipour V.; Almasi-Hashiani A.; Al-Raddadi R.M.; Alvis-Guzman N.; Amini S.; Andrei T.; Andrei C.L.; Andualem Z.; Anjomshoa M.; Arabloo J.; Ashagre A.F.; Asmelash D.; Ataro Z.; Atout M.M.W.; Ayanore M.A.; Badawi A.; Bakhtiari A.; Ballew S.H.; Balouchi A.; Banach M.; Barquera S.; Basu S.; Bayih M.T.; Bedi N.; Bello A.K.; Bensenor I.M.; Bijani A.; Boloor A.; Borzì A.M.; Cámera L.A.; Carrero J.J.; Carvalho F.; Castro F.; Catalá-López F.; Chang A.R.; Chin K.L.; Chung S-C.; Cirillo M.; Cousin E.; Dandona L.; Dandona R.; Daryani A.; Das Gupta R.; Demeke F.M.; Demoz G.T.; Desta D.M.; Do H.P.; Duncan B.B.; Eftekhari A.; Esteghamati A.; Fatima S.S.; Fernandes J.C.; Fernandes E.; Fischer F.; Freitas M.; Gad M.M.; Gebremeskel G.G.; Gebresillassie B.M.; Geta B.; Ghafourifard M.; Ghajar A.; Ghith N.; Gill P.S.; Ginawi I.A.; Gupta R.; Hafezi-Nejad N.; Haj-Mirzaian A.; Haj-Mirzaian A.; Hariyani N.; Hasan M.; Hasankhani M.; Hasanzadeh A.; Hassen H.Y.; Hay S.I.; Heidari B.; Herteliu C.; Hoang C.L.; Hosseini M.; Hostiuc M.; Irvani S.S.N.; Islam S.M.S.; Jafari Balalami N.; James S.L.; Jassal S.K.; Jha V.; Jonas J.B.; Joukar F.; Jozwiak J.J.; Kabir A.; Kahsay A.; Kasaeian A.; Kassa T.D.; Kassaye H.G.; Khader Y.S.; Khalilov R.; Khan E.A.; Khan M.S.; Khang Y-H.; Kisa A.; Kovesdy C.P.; Kuate Defo B.; Kumar G.A.; Larsson A.O.; Lim L-L.; Lopez A.D.; Lotufo P.A.; Majeed A.; Malekzadeh R.; März W.; Masaka A.; Meheretu H.A.A.; Miazgowski T.; Mirica A.; Mirrakhimov E.M.; Mithra P.; Moazen B.; Mohammad D.K.; Mohammadpourhodki R.; Mohammed S.; Mokdad A.H.; Morales L.; Moreno Velasquez I.; Mousavi S.M.; Mukhopadhyay S.; Nachega J.B.; Nadkarni G.N.; Nansseu J.R.; Natarajan G.; Nazari J.; Neal B.; Negoi R.I.; Nguyen C.T.; Nikbakhsh R.; Noubiap J.J.; Nowak C.; Olagunju A.T.; Ortiz A.; Owolabi M.O.; Palladino R.; Pathak M.; Poustchi H.; Prakash S.; Prasad N.; Rafiei A.; Raju S.B.; Ramezanzadeh K.; Rawaf S.; Rawaf D.L.; Rawal L.; Reiner R.C.; Rezapour A.; Ribeiro D.C.; Roever L.; Rothenbacher D.; Rwegerera G.M.; Saadatagah S.; Safari S.; Sahle B.W.; Salem H.; Sanabria J.; Santos I.S.; Sarveazad A.; Sawhney M.; Schaeffner E.; Schmidt M.I.; Schutte A.E.; Sepanlou S.G.; Shaikh M.A.; Sharafi Z.; Sharif M.; Sharifi A.; Silva D.A.S.; Singh J.A.; Singh N.P.; Sisay M.M.M.; Soheili A.; Sutradhar I.; Teklehaimanot B.F.; Tesfay B.; Teshome G.F.; Thakur J.S.; Tonelli M.; Tran K.B.; Tran B.X.; Tran Ngoc C.; Ullah I.; Valdez P.R.; Varughese S.; Vos T.; Vu L.G.; Waheed Y.; Werdecker A.; Wolde H.F.; Wondmieneh A.B.; Wulf Hanson S.; Yamada T.; Yeshaw Y.; Yonemoto N.; Yusefzadeh H.; Zaidi Z.; Zaki L.; Zaman S.B.; Zamora N.; Zarghi A.; Zewdie K.A.; Ärnlöv J.; Coresh J.; Perico N.; Remuzzi G.; Murray C.J.L.; Vos T.; Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020,395(10225),709-733 - DOI - PubMed
    1. Akchurin O.M.; Kaskel F.; Update on inflammation in chronic kidney disease. Blood Purif 2015,39(1-3),84-92 - DOI - PubMed
    1. Stenvinkel P.; Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant 2002,17(90008),33-38 - DOI - PubMed

MeSH terms